When the Oncologist Becomes the Cancer Patient

Article

An interesting interview aired yesterday on NPR's Fresh Air. During a routine mammogram on Dr Marisa Weiss, a breast cancer oncologist and founder of breastcancer.org, a tumor was discovered.

An interesting interview with Dr Marisa Weiss, a breast cancer oncologist and founder of breastcancer.org, aired yesterday on NPR's Fresh Air. At age 50 doctors discovered a tumor in her breast during a routine mammogram. Their conversation jumps from her personal experience as a patient and doctor to the latest issues in the field of oncology.

Here is Dr Weiss on mammograms:

"I believe strongly that women should get their first mammogram starting at age 40 and have it each year after that - and start even earlier if they're at higher risk. The taskforce guidelines that came out in November of 2009 recommend that women start getting mammograms at age 50 and then do it every other year. And they base that on old-fashioned studies using old-fashioned technology: film mammography instead of what we have today which is digital mammography. And they use that old-fashioned literature to make futuristic predictions."

Click the link below to read more or to listen to the full interview:
A Breast Oncologist, Diagnosed With The Disease

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content